Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29171
Title: Utility of repeated antinuclear antibody tests: a retrospective database study.
Authors: Leech M. ;Ong J.;Connelly K. ;Ojaimi S. ;Nim H.;Morand E.F. ;Yeo A.L. ;Le S. 
Monash Health Department(s): Immunology and Allergy
Rheumatology
Institution: (Yeo, Le, Ong, Connelly, Morand, Leech) Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia (Nim) School of Biological Sciences, Monash University, Clayton, VIC, Australia (Yeo, Connelly, Morand, Leech) Department of Rheumatology, Monash Health, Clayton, VIC, Australia (Ojaimi) Department of Immunology, Monash Health, Clayton, VIC, Australia
Issue Date: 24-Aug-2020
Copyright year: 2020
Publisher: Lancet Publishing Group (E-mail: cususerv@lancet.com)
Place of publication: United Kingdom
Publication information: The Lancet Rheumatology. 2 (7) (pp e412-e417), 2020. Date of Publication: July 2020.
Journal: The Lancet Rheumatology
Abstract: Background: Anti-nuclear antibody (ANA) testing is frequently used as a diagnostic or screening test in patients with inflammatory or musculoskeletal symptoms. The value of repeat testing is unclear. We sought to evaluate the frequency, utility, and cost of repeat ANA testing. The main objective was to assess the positive predictive value of a repeat ANA test for the diagnosis of rheumatological conditions associated with ANA. Method(s): In this retrospective cohort study, we analysed data from a single, multisite tertiary health network in Australia across a 7-year period. ANA and other autoimmune test results were obtained from the hospital pathology system with a positive ANA titre cutoff set at 1:160. Clinical information was sourced from clinical information systems on any patient who had a change in ANA result from negative to positive on repeat testing. The cost of repeated ANA testing was calculated using the Australian Government Medicare Benefits Schedule. Finding(s): From March 19, 2011, to July 23, 2018, a total of 36 715 ANA tests were done in 28 840 patients at a total cost of US$675 029 (2018 equivalent). 14 058 (38.3%) of these ANA tests were positive. 7875 (21.4%) of the ordered tests were repeats in 4887 (16.9%) of the patients, among whom 2683 (54.9%) had initially negative tests, and 2204 (45.1%) had initially positive tests. 511 (19.0%) of the 2683 patients with initially negative tests had a positive result on at least one repeat test, with a median time to first positive result of 1.74 years (IQR 0.54-3.60). A change from negative to positive ANA was associated with a new diagnosis in only five (1.1%) of the 451 patients with clinical information available and no previous diagnosis of an ANA-associated rheumatological condition, yielding a positive predictive value of 1.1% (95% CI 0.4-2.7). Interpretation(s): Repeat ANA testing after a negative result has low utility and results in high cost. Funding(s): Monash Health.Copyright © 2020 Elsevier Ltd
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/S2665-9913%2820%2930084-9
ISSN: 2665-9913 (electronic)
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/29171
Type: Article
Subjects: *immunoassay
major clinical study
male
medicare
predictive value
priority journal
reference value
*repeat procedure
retrospective study
rheumatic disease/di [Diagnosis]
rheumatic disease/dm [Disease Management]
tertiary health care
aged
human
Australia
cohort analysis
controlled study
cost utility analysis
*diagnostic value
disease association
female
health care cost
adult
*antinuclear antibody/ec [Endogenous Compound]
antibody detection
article
immunoassay
medicare
reference value
repeat procedure
rheumatic disease
tertiary health care
aged
Australia
cost utility analysis
diagnostic value
health care cost
antinuclear antibody
antibody detection
tertiary health care
adult
aged
antibody detection
Article
Australia
cohort analysis
controlled study
cost utility analysis
*diagnostic value
disease association
female
health care cost
human
*immunoassay
major clinical study
male
medicare
predictive value
priority journal
reference value
*repeat procedure
retrospective study
rheumatic disease / diagnosis / disease management
Type of Clinical Study or Trial: Observational study (cohort, case-control, cross sectional or survey)
Appears in Collections:Articles

Show full item record

Page view(s)

90
checked on Aug 15, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.